These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 24573113)

  • 1. Outcome and cost analysis of induction immunosuppression with IL2Mab or ATG in DCD kidney transplants.
    Popat R; Syed A; Puliatti C; Cacciola R
    Transplantation; 2014 Jun; 97(11):1161-5. PubMed ID: 24573113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients.
    Lü TM; Yang SL; Wu WZ; Tan JM
    Chin Med J (Engl); 2011 Mar; 124(5):664-8. PubMed ID: 21518554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-2 receptor antagonist compared with antithymocyte globulin induction therapy in kidney transplantation from donors after cardiac death.
    Peng W; Liu G; Xie W; Huang H; Wu J; Shou Z; Chen J
    Int J Clin Pract Suppl; 2015 May; (183):23-8. PubMed ID: 26177071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation.
    Farney AC; Doares W; Rogers J; Singh R; Hartmann E; Hart L; Ashcraft E; Reeves-Daniels A; Gautreaux M; Iskandar SS; Moore P; Adams PL; Stratta RJ
    Transplantation; 2009 Sep; 88(6):810-9. PubMed ID: 19920781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alemtuzumab induction and triple maintenance immunotherapy in kidney transplantation from donors after cardiac death.
    Schadde E; D'Alessandro AM; Knechtle SJ; Odorico J; Becker Y; Pirsch J; Sollinger H; Fernandez LA
    Transpl Int; 2008 Jul; 21(7):625-36. PubMed ID: 18397178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness of Antibody-Based Induction Therapy in Deceased Donor Kidney Transplantation in the United States.
    Gharibi Z; Ayvaci MUS; Hahsler M; Giacoma T; Gaston RS; Tanriover B
    Transplantation; 2017 Jun; 101(6):1234-1241. PubMed ID: 27379555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Cost-effectiveness Analysis of Rabbit Antithymocyte Globulin Versus Antithymocyte Globulin-fresenius as Induction Therapy for Patients With Kidney Transplantation From Donation After Cardiac Death in China.
    Xuan D; Chen G; Wang C; Yao X; Yin H; Zhang L; Xuan J; Chen L
    Clin Ther; 2018 Oct; 40(10):1741-1751. PubMed ID: 30243768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and economic outcomes of rabbit antithymocyte globulin induction in adults who received kidney transplants from living unrelated donors and received cyclosporine-based immunosuppression.
    Miller JT; Collins CD; Stuckey LJ; Luan FL; Englesbe MJ; Magee JC; Park JM
    Pharmacotherapy; 2009 Oct; 29(10):1166-74. PubMed ID: 19792990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kidney transplantation from donation after cardiac death donors: lack of impact of delayed graft function on post-transplant outcomes.
    Singh RP; Farney AC; Rogers J; Zuckerman J; Reeves-Daniel A; Hartmann E; Iskandar S; Adams P; Stratta RJ
    Clin Transplant; 2011; 25(2):255-64. PubMed ID: 20331689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome of induction immunosuppression for liver transplantation comparing anti-thymocyte globulin, daclizumab, and corticosteroid.
    Uemura T; Schaefer E; Hollenbeak CS; Khan A; Kadry Z
    Transpl Int; 2011 Jul; 24(7):640-50. PubMed ID: 21429047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunosuppression with antithymocyte globulin in renal transplantation: better long-term graft survival.
    Martins L; Fonseca I; Almeida M; Henriques AC; Dias L; Sarmento AM; Cabrita A
    Transplant Proc; 2005; 37(6):2755-8. PubMed ID: 16182802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MALG vs OKT3 following renal transplantation: a randomized prospective trial.
    Frey DJ; Matas AJ; Gillingham KJ; Canafax D; Payne WD; Dunn DL; Sutherland DE; Najarian JS
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1048-9. PubMed ID: 1899149
    [No Abstract]   [Full Text] [Related]  

  • 13. Antilymphocyte induction immunosuppression in the post-Minnesota anti-lymphocyte globulin era: incidence of renal dysfunction and delayed graft function. A single center experience.
    Malinow L; Walker J; Klassen D; Oldach D; Schweitzer E; Bartlett ST; Weir MR
    Clin Transplant; 1996 Jun; 10(3):237-42. PubMed ID: 8826659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination treatment of low dose Anti-Thymocyte Globulin (ATG), Rituximab and high dose Sirolimus as induction agents in immune-conditioned recipients.
    Ravichandran P; Natrajan T; Jaganathan R
    Int Immunopharmacol; 2006 Dec; 6(13-14):1973-6. PubMed ID: 17161350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cadaveric kidney transplantation under prophylactic polyclonal antibody immunosuppression with anti-lymphoblast globulin versus anti-thymocyte globulin.
    Indudhara R; Novick AC; Hodge E; Goormastic M; Papajcik D; Mastroianni B; Cook D
    Urology; 1996 Jun; 47(6):807-12. PubMed ID: 8677568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation.
    Uslu A; Nart A; Taşli FA; Postaci H; Aykas A; Doğan M; Sahin T
    Nephrology (Carlton); 2008 Feb; 13(1):80-6. PubMed ID: 18199109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of delayed graft function and acute rejection on outcomes after kidney transplantation from donors after cardiac death.
    Nagaraja P; Roberts GW; Stephens M; Horvath S; Fialova J; Chavez R; Asderakis A; Kaposztas Z
    Transplantation; 2012 Dec; 94(12):1218-23. PubMed ID: 23154212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PREventing Delayed Graft Function by Driving Immunosuppressive InduCtion Treatment (PREDICT-DGF): study protocol for a randomized controlled trial.
    Chapal M; Foucher Y; Marguerite M; Neau K; Papuchon E; Daguin P; Morélon E; Mourad G; Cassuto E; Ladrière M; Legendre C; Giral M
    Trials; 2015 Jun; 16():282. PubMed ID: 26099226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective randomized comparison of prophylactic ALG and OKT3 in cadaver kidney allograft recipients.
    Hanto DW; Jendrisak MD; McCullough CS; So SK; Marsh JW; Rush T; Michalski S; Phelan D; Mohanakumar T
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1050-1. PubMed ID: 1899150
    [No Abstract]   [Full Text] [Related]  

  • 20. Single-shot antithymocyte globulin (ATG) induction for pancreas/kidney transplantation: ATG-Fresenius versus Thymoglobulin.
    Schulz T; Papapostolou G; Schenker P; Kapischke M
    Transplant Proc; 2005 Mar; 37(2):1301-4. PubMed ID: 15848703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.